Australia is currently observing the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist , representing a potential advance in obesity treatment . Early research findings have demonstrated https://bike-giant-talon-2630299.wikiparticularization.com/2723087/emerging_medication_in_australia_a_potential_solution_for_obesity_management